{
    "clinical_study": {
        "@rank": "65405", 
        "arm_group": {
            "arm_group_label": "All participants", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Patients are being asked to take part because they have melanoma that has spread to other\n      organs in their body (metastatic). As part of this study, patients will receive radiation\n      therapy and an approved drug (Vemurafenib)."
        }, 
        "brief_title": "Radiation Use During Vemurafenib Treatment", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "BRAFV600 Mutation", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Patients will be treated with vemurafenib plus radiation therapy (RT) based upon the\n      administration schedule.  The starting dose of vemurafenib will be the patient's baseline\n      tolerating dose, between 720 - and 960 mg by mouth.  Patients must be tolerating at a\n      minimum 720mg for one cycle (28 days) prior to enrollment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years old\n\n          -  Diagnosis of BRAFV600 mutated Stage IV or unresectable Stage III melanoma\n\n          -  Actively receiving treatment with vemurafenib as single agent and tolerating at least\n             720 mg bid for one cycle (28 days).\n\n          -  In the opinion of the investigator, patients who are progressing in an area where\n             radiation may provide benefit from either:\n\n               -  Symptom control\n\n               -  Oligo-progression, defined as progression in up to 3 areas where focal treatment\n                  would provide benefit.\n\n          -  Patients with brain metastases will be allowed provided they meet all of the\n             following criteria:\n\n               -  Small, < 1cm metastases which are untreated are allowed so long as in the\n                  opinion of the investigator they do not require immediate treatment by radiation\n                  or surgery\n\n               -  Asymptomatic, treated brain metastases which are stable for 4 weeks prior to\n                  study entry are allowed\n\n               -  If patients are requiring steroids for their brain metastases, they must be on a\n                  stable dose for two weeks prior to study entry, and maintain that steroid dosing\n                  during the radiation treatments\n\n          -  Adequate bone marrow function as defined by: ANC > 1.0 k/uL, Platelets > 75 k/uL,\n             Hemoglobin  > 8 g/dL\n\n          -  Adequate hepatic function: Total bilirubin < 1.5 times the institutional upper limit\n             of normal, ALT/AST < 2.5 times the institutional upper limit of normal\n\n          -  Adequate renal function as defined by serum creatinin < 1.5 times the upper limit of\n             normal.\n\n          -  Negative serum pregnancy test at screening for women of child bearing potential\n             within 10 days of starting vemurafenib treatment .  Women of non-childbearing\n             potential may be included if they are either surgically sterile or have been\n             postmenopausal for > 1 year\n\n          -  Fertile men and women must agree to use an acceptable method of birth control during\n             treatment and for at least 2 months after discontinuation of vemurafenib.\n\n          -  Able and willing to provide informed consent to an approved consent form that\n             conforms to federal and institutional guidelines.\n\n        Exclusion Criteria:\n\n          -  Screening QTc interval > 450 msec on EKG\n\n          -  Known HIV positivity or AIDS-related illness, or active HBV, or active HCV.\n\n          -  Any of the following within the 6 months prior to study drug administration:\n             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass\n             graft, symptomatic congestive heart failure, serious cardiac arrhythmia requiring\n             medication, uncontrolled hypertension, cerebrovascular accident or transient ischemic\n             attack, or symptomatic pulmonary embolism.\n\n          -  Malabsorption disorder that would preclude adequate vemurafenib absorption.\n\n          -  Other medical condition present that in the opinion of the investigator will hinder\n             the subjects ability to complete the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843738", 
            "org_study_id": "HCI64498"
        }, 
        "intervention": [
            {
                "arm_group_label": "All participants", 
                "intervention_name": "Radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "All participants", 
                "description": "The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.", 
                "intervention_name": "Vemurafenib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84112"
                }, 
                "name": "Huntsman Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Kenneth Grossmann, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "darren.walker@hci.utah.edu", 
            "last_name": "Darren Walker", 
            "phone": "801-587-4323"
        }, 
        "overall_official": {
            "affiliation": "Huntsman Cancer Institute", 
            "last_name": "Kenneth Grossmann, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety of radiation combined with vemurafenib treatment in patients with BRAFV600 mutated Stage IV or unresectable Stage III melanoma", 
            "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843738"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate response rates as assessed by RECIST criteria 1.1, at baseline, and at 8 week intervals throughout the study", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}